Search Presidential Documents

Executive orders, proclamations, memoranda, determinations, and other instruments — filter by administration, type, and theme.

7 shown · Trump 47 · Commissioner of Food and Drugs

EO 144012026-04-18Trump

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs federal agencies to accelerate research, regulatory review, and patient access to psychedelic drugs (including ibogaine compounds) for treating serious mental illness and reducing suicide rates. It creates FDA priority vouchers for breakthrough-designated psychedelics, establishes Right to Try access pathways, funds state-federal collaboration through ARPA-H, mandates interagency data sharing with VA, and requires timely DEA rescheduling of approved psychedelic products.

EO 143792026-01-29Trump

Addressing Addiction Through the Great American Recovery Initiative

This executive order establishes the White House Great American Recovery Initiative, co-chaired by the Secretary of HHS and a Senior Advisor for Addiction Recovery, to coordinate federal response to substance use disorder. The Initiative brings together 15+ officials across cabinet departments and agencies to recommend steps for aligning federal programs, increasing treatment access, and integrating addiction services across health, criminal justice, workforce, education, and housing systems.

EO 143702025-12-18Trump

Increasing Medical Marijuana and Cannabidiol Research

This executive order directs the Attorney General to expedite rescheduling marijuana from Schedule I to Schedule III of the Controlled Substances Act to facilitate medical research. It also directs multiple health agencies to develop research methods using real-world evidence for medical marijuana and hemp-derived CBD products, and tasks White House legislative staff with working Congress to update statutory definitions for hemp-derived cannabinoids.

EO 142972025-05-12Trump

Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients

This executive order directs the Administration to pursue most-favored-nation prescription drug pricing, requiring pharmaceutical manufacturers to offer U.S. patients prices comparable to other developed nations or face potential rulemaking, importation waivers, antitrust enforcement, export reviews, and FDA approval modifications. It establishes a 30-day deadline for HHS to communicate price targets to drug makers, with escalating measures if progress is not achieved.

EO 142932025-05-05Trump

Regulatory Relief To Promote Domestic Production of Critical Medicines

This executive order directs federal agencies to streamline regulatory and permitting processes for domestic pharmaceutical manufacturing, with specific actions by FDA, EPA, Army Corps of Engineers, and OMB. It also mandates increased inspections and fees on foreign manufacturing facilities and requires public disclosure of foreign inspection data, aiming to reduce domestic facility construction timelines from 5-10 years and shift production back to the United States.

EO 142732025-04-15Trump

Lowering Drug Prices by Once Again Putting Americans First

This executive order directs multiple federal agencies to take steps to lower prescription drug prices, primarily by modifying the Medicare Drug Price Negotiation Program created by the Inflation Reduction Act, promoting generic and biosimilar competition, expanding drug importation, increasing transparency in pharmacy benefit manager compensation, and conditioning health center grants on providing discounted insulin and epinephrine to low-income patients.

EO 142122025-02-13Trump

Establishing the President's Make America Healthy Again Commission

This executive order establishes the President's Make America Healthy Again Commission, chaired by the HHS Secretary, to combat rising chronic disease rates in America with an initial focus on childhood chronic disease. The Commission must produce an assessment within 100 days and a strategy within 180 days on causes including diet, environmental factors, medical treatments, and corporate influence, while directing multiple agencies to prioritize disease prevention, research integrity, and healthy food production.

Loading search…